



February 11, 2026

Sen. Deb Patterson, Chair
Senate Committee on Health Care

Testimony – Support for SB 1528 –2 Amendment

- We support SB 1528 because it closes a major gap in Oregon’s Drug Price Transparency law. Under current statute, information about manufacturer Patient Assistance Programs is only reported when a drug has a qualifying price increase. If a drug did not trigger a price-increase report, the state received no information about the assistance programs tied to that drug.
- The Bill fixes that by creating a clear, stand-alone, annual reporting requirement for all manufacturer-funded Patient Assistance Programs. For the first time, manufacturers must report every year on every program that actually provided assistance to Oregonians — not just those connected to a price-increased drug.
- This gives Oregon a far more complete picture of how Patient Assistance Programs influence drug affordability. While Patient Assistance Programs can and do help patients afford needed medications, these Programs can also mask the impact of high list prices, steer patients toward costlier drugs, or undermine generic competition. Annual reporting lets the state finally see the full landscape and evaluate what’s working and what isn’t.
- SB 1528 improves accountability and transparency without creating burdens for patients or providers. Reporting responsibility sits where it belongs — with drug manufacturers — and ensures Oregonians benefit from better visibility into pricing practices.
- SB 1528 is good for Oregonians because it supports smarter policymaking, better consumer protection, and a clearer understanding of the real cost drivers in prescription drug pricing. More complete data allows Oregon to monitor affordability, identify problematic pricing behavior, and design solutions that protect patients, employers, and insurers from hidden cost pressures.

Sincerely,

Robert Judge
Chief Client Officer Pharmacy Solutions

Health plans provided by Moda Health Plan, Inc.